Life Clinical Trials

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Lupus (SLE)4 trials
• Psoriasis3 trials
• Gout2 trials
• Obesity2 trials
• Psoriatic arthritis2 trials
• Rheumatoid arthritis2 trials
• Dermatomyositis and polymyositis (myositis)1 trial
• Systemic sclerosis (scleroderma)1 trial

Phase

• Phase 35 trials
• Phase 44 trials
• Phase 22 trials

Status

• Active, not recruiting4 trials
• Completed3 trials
• Recruiting3 trials
• Enrolling by invitation1 trial
• Suspended1 trial
• Terminated1 trial

Lead sponsor

• Amgen2 trials
• Biogen2 trials
• Bristol-Myers Squibb2 trials
• Eli Lilly and Company2 trials
• Aqtual, Inc.1 trial
• and 4 more

Running trials

• Recruiting

  PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

  NCT07611214· Phase 4· Aurinia Pharmaceuticals Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

  NCT06979453· Phase 3· Bristol-Myers Squibb· Source

  Contact: Eli Saleeby, Site 0185

• Recruiting

  A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

  NCT07175285· Bristol-Myers Squibb· Source

  Contact: Jigar Shah, Site 0006

• Active, not recruiting

  A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

  NCT06864026· Phase 4· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

  NCT06284954· Phase 2· argenx· Source

• Active, not recruiting

  Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD

  NCT05936970· Aqtual, Inc.· Source

• Enrolling by invitation

  A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

  NCT05352919· Phase 3· Biogen· Source

• Active, not recruiting

  A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

  NCT04895241· Phase 3· Biogen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lupus (SLE)3 recruiting
• Psoriasis1 recruiting

Closed trials

• Completed

  Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

  NCT06588296· Phase 3· Eli Lilly and Company· Source

• Completed

  A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

  NCT06229145· Phase 4· Amgen· Source

• Terminated

  Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

  NCT05246280· Phase 3· Navidea Biopharmaceuticals· Source

• Completed

  Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

  NCT04511702· Phase 4· Amgen· Source